source
- Vaxcyte's next-gen pneumococcal vaccine matches leading shots in Phase 3 trialVaxcyte reported that its experimental pneumococcal vaccine, VAX-31, achieved its primary efficacy goals in the first of three Phase 3 studies. In adults aged 50 and older, the vaccine performed o…
- Vaxcyte’s pneumococcal vaccine meets primary goals in Phase 3 trial, challenging Pfizer and MerckVaxcyte announced that its experimental pneumococcal vaccine, VAX-31, achieved the primary endpoints in a pivotal Phase 3 study. The data, presented in a company release, show the shot met its pred…